Tumor-reactive superantigens suppress tumor growth in humanized SCID mice.

Abstract	Superantigens are extremely potent activators of T lymphocytes. To develop a tumor-reactive superantigen for cancer therapy, we made a recombinant fusion protein of the superantigen staphylococcal enterotoxin A (SEA) and the Fab region of the C242 monoclonal antibody (C242Fab-SEA), which recognize human colon carcinoma cells. The therapeutic effect of C242Fab-SEA on colon-cancer growth was examined in lymphocyte-engrafted humanized SCID mice bearing intraperitoneally growing Colo205 colon carcinomas. i.v. injections of C242Fab-SEA significantly inhibited tumor growth. The anti-tumor effect required the presence of human T cells in the SCID mice. Optimal therapeutic effects were seen with C242Fab-SEA, but not with C242Fab fragment or SEA alone, demonstrating that both entities of the fusion protein were required. C242Fab-SEA-treated tumors showed a massive infiltration of T cells in the tumor parenchyme, and was accompanied by enhanced expression of ICAM-I and HLA-DR on the tumor cells. The results demonstrate that Fab-SEA fusion proteins convey superantigenicity on tumor cells which evoke T-cell-dependent suppression of tumor growth.
Authors	P A Lando, M Dohlsten, L Ohlsson, T Kalland
Journal	International journal of cancer (Int J Cancer) Vol. 62 Issue 4 Pg. 466-71 (Aug 09 1995) ISSN: 0020-7136 [Print] United States
PMID	7635573 (Publication Type: Journal Article)
Chemical References	Antibodies, Monoclonal Enterotoxins HLA-DR Antigens Immunoglobulin Fab Fragments Recombinant Fusion Proteins Superantigens Intercellular Adhesion Molecule-1 enterotoxin A, Staphylococcal
Topics	Animals Antibodies, Monoclonal (therapeutic use) Colonic Neoplasms (immunology, metabolism, therapy) Enterotoxins (therapeutic use) Female HLA-DR Antigens (metabolism) Humans Immunoglobulin Fab Fragments (immunology, therapeutic use) Intercellular Adhesion Molecule-1 (metabolism) Lymphocytes, Tumor-Infiltrating (immunology) Mice Mice, SCID Neoplasm Transplantation Recombinant Fusion Proteins (therapeutic use) Superantigens (therapeutic use) T-Lymphocytes (immunology) Transplantation, Heterologous Tumor Cells, Cultured Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!